#GCTK hashtag - Bluesky

Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a

1 week ago

#GCTK Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones

www.stocktitan.net/news/GCTK/glucotrack-to-...

0 0 0 0

Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor Glucotrack (Nasdaq: GCTK) entered a securities purchase agreement dated Dec 30, 2025, with a single institutional investor to sell 1,033,591 common shares (or equivalents) plus warrants to buy up to 2,067,182 shares at a combined effective price of $3.87 per share, for aggregate gross proceeds of approximately $4.0 million before fees.The warrants carry a $3.87 exercise price, expire five years from initial exercise, and are not exercisable until shareholder approval. Closing is expected on or about Dec 31, 2025. Proceeds are planned for working capital and general corporate purposes. Curvature Securities is sole placement agent. The company agreed to file resale registration within 15 days of closing and use efforts to have it effective within 45 days.

3 months ago

#GCTK Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor

www.stocktitan.net/news/GCTK/glucotrack-inc...

0 0 0 0

4 months ago

#GCTK Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

www.stocktitan.net/news/GCTK/glucotrack-rep...

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

BREAKING NEWS: ( NASDAQ: #GCTK ) US Companies Moving the Markets, Evening edition <br>Fri, Sep 12, 2025 as of 4:00 pm ET

0 0 0 0

Market Wire News

@marketwirenews.com

6 months ago

News; ( NASDAQ: #GCTK ) Biotech Breakouts & Bitcoin Bets

0 0 0 0

Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Glucotrack (NASDAQ:GCTK), a medical technology company developing novel diabetes technologies, reported significant progress in Q2 2025. The company is preparing to launch a multicenter feasibility study of its fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025, followed by an FDA IDE submission in Q4 2025.Key developments include strengthening the leadership team with Dr. David Hirsh as Medical Director-Cardiology and Dr. Victoria Carr-Brendel joining the Board. Clinical data presented at the ADA conference showed excellent accuracy with a MARD of 7.7% and 99% data capture rate. The company reported $9.6 million in cash as of June 30, 2025, sufficient to fund operations through 2025.Financial results showed R&D expenses of $5.0 million and net loss of $11.6 million for H1 2025. The company strengthened its capital structure by repurchasing Series A Warrants to eliminate warrant liability and dilution concerns.

7 months ago

#GCTK Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/GCTK/glucotrack-rep...

0 0 0 0

Revolutionary 3-Year Implantable Diabetes Monitor Advances as Glucotrack Strengthens Medical Leadership Cardiac expert joins to advance breakthrough implantable glucose monitor lasting 3 years with direct blood measurement. Key milestone for diabetes care innovation. Learn more.

7 months ago

#GCTK Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology

www.stocktitan.net/news/GCTK/glucotrack-exp...

0 0 0 0

Revolutionary Blood Glucose Monitor Lasts 3 Years Without Wearables - Glucotrack Reveals Next Evolution in Diabetes Care Discover how this implantable blood glucose monitor eliminates daily sensor changes and works for 3 years. New clinical validation data to be presented. Learn more.

8 months ago

#GCTK Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting

www.stocktitan.net/news/GCTK/glucotrack-to-...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Jul 21st - #OPAD #SLDP #ABCL #UPXI #RXRX #GCTK #SABS #DNN #RAYA #LMFA #EOSE #SBET #HSDT #OPEN #BMNR #SRPT #AZ #ARQQ #RZLV #AAOI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Diabetes Tech Company Glucotrack Eliminates Major Dilution Risk with Strategic 90% Warrant Repurchase Diabetes device maker strengthens capital structure by buying back 49,700 Series A Warrants. Learn how this strategic move impacts shareholder value. See details.

8 months ago

#GCTK Glucotrack Announces Repurchase of Series A Warrants

www.stocktitan.net/news/GCTK/glucotrack-ann...

0 0 0 0

trending stonks

@trendingstocks.bsky.social

9 months ago

🚨 $GCTK 🚨

Why is GlucoTrack, Inc. trending today? 🤔

#GCTK #stocks #stockmarket

0 0 0 0

Market Wire News

@marketwirenews.com

9 months ago

NEWS: ( NASDAQ: #GCTK ) Top Stocks to Watch: June 25, 2025 Edition

0 0 0 0

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements Glucotrack (NASDAQ: GCTK) announced a 1-for-60 reverse stock split effective June 16, 2025, aimed at maintaining its NASDAQ listing compliance. The company's outstanding common stock will be reduced from 32,541,327 to approximately 542,356 shares, with stockholders' ownership percentages remaining unchanged except for fractional shares being rounded up. The split was approved by shareholders on May 22, 2025, authorizing management to implement a ratio up to 1-for-100. This strategic move is primarily intended to meet NASDAQ's $1.00 minimum bid price requirement and attract institutional life science investors. The company must maintain compliance with NASDAQ listing rules through September 29, 2025, to avoid potential delisting.

9 months ago

#GCTK Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

www.stocktitan.net/news/GCTK/glucotrack-ann...

0 0 0 0

Revolutionary Diabetes Tech: Glucotrack's 3-Year Implantable Monitor Eliminates Daily Finger Pricks First-in-human trial data reveals breakthrough in continuous blood glucose monitoring. No wearables needed, lasts 3 years. See clinical results from ADA Scientific Sessions.

10 months ago

#GCTK Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions

www.stocktitan.net/news/GCTK/glucotrack-to-...

0 0 0 0

Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Glucotrack (NASDAQ: GCTK) reported its Q1 2025 financial results and corporate updates. The company is advancing its fully implantable continuous blood glucose monitor (CBGM) system, with plans to begin patient implants in Australia in Q3 2025 and expected FDA IDE approval in Q4 2025. Key developments include ethical approval in Australia for clinical studies, participation in FORGETDIABETES European research initiative, and collaboration with OneTwo Analytics for AI-driven data analysis. Financial results showed R&D expenses of $1.9M (down from $2.1M in Q1 2024), while MG&A expenses increased to $1.6M (from $0.8M). Net loss widened to $6.8M (from $2.9M), primarily due to derivative liabilities changes. The company's cash position strengthened to $9.1M as of March 31, 2025, which is expected to fund its 2025 operating plan including clinical trials.

10 months ago

#GCTK Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/GCTK/glucotrack-rep...

0 0 0 0

Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor Glucotrack (NASDAQ: GCTK) has received ethical approval from St. Vincent's Hospital Melbourne HREC for a long-term clinical study of its continuous blood glucose monitor (CBGM) for diabetes patients. The study will enroll up to 30 participants with type 1 and type 2 diabetes mellitus, initially running for 1 year with potential extension to 3 years.The study will be led by Professor David O'Neal and Associate Professor Neale Cohen, with first patient implants expected by July 2025. Glucotrack's CBGM is a long-term implantable system designed for up to three years of continuous monitoring, featuring no wearable components and direct blood glucose measurement, unlike traditional systems that measure from interstitial fluid.The approval follows Glucotrack's successful first-in-human study, marking a significant advancement in their clinical program.

10 months ago

#GCTK Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

www.stocktitan.net/news/GCTK/glucotrack-ann...

0 0 0 0

Game-Changing Implantable Glucose Monitor Partners With AI Firm for 3-Year Clinical Study AI-powered analysis begins for groundbreaking implantable glucose monitor that measures blood directly, promising 3 years of external component-free diabetes management.

1 year ago

#GCTK Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

www.stocktitan.net/news/GCTK/glucotrack-and...

0 0 0 0

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights Glucotrack (NASDAQ: GCTK) reported its full year 2024 financial results, marking a transformative year as the company advanced from preclinical to clinical stage. The company successfully completed its first human clinical study of the continuous blood glucose monitor (CBGM), which met its primary endpoint with no serious adverse events.Key financial highlights include: R&D expenses increased to $9.5M (vs $4.7M in 2023)Marketing and administrative expenses rose to $5.1M (vs $2.4M in 2023)Net loss widened to $22.6M (vs $7.1M in 2023)Cash position of $5.6M as of December 31, 2024Secured $16.3M through multiple funding rounds from November 2024 through March 2025The company expects FDA IDE approval for their CBGM technology in Q4 2025 and plans to commence a long-term multicenter feasibility study in Australia in Q2 2025. Their CBGM technology will be the first fully implantable system with a multi-year monitoring capability and real-time measuring features.

1 year ago

#GCTK Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/GCTK/glucotrack-rep...

0 0 0 0

1 year ago

Bearish vibes for #GCTK! 📉 Trading at $0.2489, it's below the 30-day SMA of $0.3785. RSI < 30 signals oversold, but MACD's still negative. Low volume adds liquidity concerns. Consider a SHORT: Entry $0.25, targets $0.24 & $0.22, stop loss $0.27. Stay sharp! #FeetrAI

0 0 0 0

1 year ago

🚀 Exciting times for #GCTK! Trading at $0.275, it's showing signs of a rebound with RSI levels hinting oversold conditions and a positive MACD histogram. Cautious bulls might eye an entry at $0.27, targeting $0.30-$0.32. Stay sharp on market trends! 📈 #FeetrAI

0 0 0 0

1 year ago

🚨 FeetrAI Alert: #GCTK is in the spotlight! Trading at $0.24 with oversold RSI & low volume, it's showing bearish vibes. MACD hints at a short-term bounce, but overall trend is down. Consider SHORT at $0.24, target $0.20/$0.18, stop loss $0.26. Stay sharp! 📉 #StockMarket

0 0 0 0

1 year ago

🚀 Exciting times for #GCTK! Trading at $0.2782, it's oversold with a positive MACD hinting at a bounce. 📈 Watch for a break above $0.29 for targets of $0.31 & $0.34. Caution advised due to low volume & market sentiment. Set stop loss at $0.26. Stay alert! #FeetrAI

0 0 0 0

1 year ago

🚨 FeetrAI Alert: #GCTK is trading at $0.29, below its 10-day SMA & 20-day EMA, signaling bearish momentum. RSI near oversold suggests a bounce, but caution! MACD hints reversal, yet low volume adds uncertainty. Consider SHORT with targets at $0.25 & $0.22. Stay sharp! 📉📊

0 0 0 0